CN101448504B - 吉西他滨酰胺前体药物的结晶形式、其组合物以及用途 - Google Patents

吉西他滨酰胺前体药物的结晶形式、其组合物以及用途 Download PDF

Info

Publication number
CN101448504B
CN101448504B CN2007800182296A CN200780018229A CN101448504B CN 101448504 B CN101448504 B CN 101448504B CN 2007800182296 A CN2007800182296 A CN 2007800182296A CN 200780018229 A CN200780018229 A CN 200780018229A CN 101448504 B CN101448504 B CN 101448504B
Authority
CN
China
Prior art keywords
deoxidation
fluoro
ribofuranosyls
aminopyrimidine
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800182296A
Other languages
English (en)
Chinese (zh)
Other versions
CN101448504A (zh
Inventor
A·Y·奥布列佐夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101448504A publication Critical patent/CN101448504A/zh
Application granted granted Critical
Publication of CN101448504B publication Critical patent/CN101448504B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN2007800182296A 2006-06-21 2007-06-20 吉西他滨酰胺前体药物的结晶形式、其组合物以及用途 Expired - Fee Related CN101448504B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81550806P 2006-06-21 2006-06-21
US81540706P 2006-06-21 2006-06-21
US60/815,508 2006-06-21
US60/815,407 2006-06-21
PCT/US2007/071613 WO2007149891A2 (en) 2006-06-21 2007-06-20 Crystalline forms of gemcitabine amide prodrug, compositions and use thereof

Publications (2)

Publication Number Publication Date
CN101448504A CN101448504A (zh) 2009-06-03
CN101448504B true CN101448504B (zh) 2012-04-11

Family

ID=38670971

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800182296A Expired - Fee Related CN101448504B (zh) 2006-06-21 2007-06-20 吉西他滨酰胺前体药物的结晶形式、其组合物以及用途

Country Status (11)

Country Link
US (1) US8114854B2 (enExample)
EP (1) EP2043653B1 (enExample)
JP (1) JP5225271B2 (enExample)
KR (1) KR101108407B1 (enExample)
CN (1) CN101448504B (enExample)
AU (1) AU2007261002B2 (enExample)
CA (1) CA2652633C (enExample)
EA (1) EA014909B1 (enExample)
ES (1) ES2446092T3 (enExample)
MX (1) MX2009000198A (enExample)
WO (1) WO2007149891A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070232A1 (en) * 2008-05-16 2011-03-24 Pharma Mar, S.A. Combination Therapy with an Antitumor Alkaloid
EP2303906B1 (en) * 2008-06-12 2016-06-08 ScinoPharm Taiwan, Ltd. Crystalline polymorphs of gemcitabine base
CN101525361B (zh) * 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
KR20150082606A (ko) 2012-11-13 2015-07-15 보옌 테라퓨틱스, 인크. 겜시타빈 전구약물 및 그의 용도
ES2712877T3 (es) 2013-10-29 2019-05-16 Otsuka Pharma Co Ltd Ruta sintética de 2’-desoxi-2’,2’-difluorotetrahidrouridinas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032762A1 (en) * 1997-01-24 1998-07-30 Norsk Hydro Asa Gemcitabine derivatives
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691827B2 (en) 2004-12-17 2010-04-06 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032762A1 (en) * 1997-01-24 1998-07-30 Norsk Hydro Asa Gemcitabine derivatives
US6384019B1 (en) * 1997-01-24 2002-05-07 Norsk Hydro Asa Gemcitabine derivatives
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
EA200970042A1 (ru) 2009-04-28
CA2652633C (en) 2014-03-25
EP2043653A2 (en) 2009-04-08
JP5225271B2 (ja) 2013-07-03
WO2007149891A2 (en) 2007-12-27
EP2043653B1 (en) 2013-12-25
KR20090033447A (ko) 2009-04-03
JP2009541344A (ja) 2009-11-26
CN101448504A (zh) 2009-06-03
EA014909B1 (ru) 2011-02-28
MX2009000198A (es) 2009-01-22
WO2007149891A3 (en) 2008-02-14
ES2446092T3 (es) 2014-03-06
US20090203640A1 (en) 2009-08-13
KR101108407B1 (ko) 2012-01-30
AU2007261002A1 (en) 2007-12-27
CA2652633A1 (en) 2007-12-27
US8114854B2 (en) 2012-02-14
AU2007261002B2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
CA2278056C (en) Gemcitabine derivatives
CN101448504B (zh) 吉西他滨酰胺前体药物的结晶形式、其组合物以及用途
IL183666A (en) Amide prodrug of gemcitabine, pharmaceutical compositions comprising the same and use thereof in the manufacture of medicaments for treatment of susceptible neoplasms
JP6769000B2 (ja) ４’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途
CN103130854A (zh) 维生素e琥珀酸酯化吉西他滨前药及应用
CN111655710B (zh) 吉西他滨含磷前药
CN1693309A (zh) N4－（取代的氧羰基）－2′，2′－二氟－2′－脱氧胞苷衍生物及其应用
KR102270538B1 (ko) 이코티닙 포스페이트의 신규한 다형체 형태 및 이의 용도
CN105085614B (zh) 一种链丝菌素甲磺酸钠及其制备方法和用途
HK1109903B (en) Amide prodrug of gemcitabine, compositions and use thereof
HK1116197A (en) Amide prodrug of gemcitabine, compositions and use thereof
KR20030009649A (ko) Ν-알키닐옥시카르보닐-5-플루오로시토신 유도체, 그제조방법 및 이를 유효성분으로 포함하는 항암제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120411

Termination date: 20160620

CF01 Termination of patent right due to non-payment of annual fee